Skip to main content
NCBI home page
Infectious Diseases in Obstetrics and Gynecology logoLink to Infectious Diseases in Obstetrics and Gynecology
. 1994;1(4):202–208. doi: 10.1155/S1064744994000098

Systemic vs. Topical Therapy for the Treatment of Vulvovaginal Candidiasis

Sebastian Faro 1,✉
PMCID: PMC2364342  PMID: 18475346

Abstract

It is estimated that 75% of all women will experience at least 1 episode of vulvovaginal candidiasis (VVC) during their lifetimes. Most patients with acute VVC can be treated with short-term regimens that optimize compliance. Since current topical and oral antifungals have shown comparably high efficacy rates, other issues should be considered in determining the most appropriate therapy. It is possible that the use of short-duration narrow-spectrum agents may increase selection of more resistant organisms which will result in an increase of recurrent VVC (RVVC). Women who are known or suspected to be pregnant and women of childbearing age who are not using a reliable means of contraception should receive topical therapy, as should those who are breast-feeding or receiving drugs that can interact with an oral azole and those who have previously experienced adverse effects during azole therapy. Because of the potential risks associated with systemic treatment, topical therapy with a broad-spectrum agent should be the method of choice for VVC, whereas systemic therapy should be reserved for either RVVC or cases where the benefits outweigh any possible adverse reactions.

Full Text

The Full Text of this article is available as a PDF (672.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abbott M., Hughes D. L., Patel R., Kinghorn G. R. Angio-oedema after fluconazole. Lancet. 1991 Sep 7;338(8767):633–633. doi: 10.1016/0140-6736(91)90643-4. [DOI] [PubMed] [Google Scholar]
  2. Baciewicz A. M., Baciewicz F. A., Jr Ketoconazole and fluconazole drug interactions. Arch Intern Med. 1993 Sep 13;153(17):1970–1976. [PubMed] [Google Scholar]
  3. Boag F. C., Houang E. T., Westrom R., McCormack S. M., Lawrence A. G. Comparison of vaginal flora after treatment with a clotrimazole 500 mg vaginal pessary or a fluconazole 150 mg capsule for vaginal candidosis. Genitourin Med. 1991 Jun;67(3):232–234. doi: 10.1136/sti.67.3.232. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Brammer K. W., Feczko J. M. Single-dose oral fluconazole in the treatment of vaginal candidosis. Ann N Y Acad Sci. 1988;544:561–563. doi: 10.1111/j.1749-6632.1988.tb40452.x. [DOI] [PubMed] [Google Scholar]
  5. Corson S. L., Kapikian R. R., Nehring R. Terconazole and miconazole cream for treating vulvovaginal candidiasis. A comparison. J Reprod Med. 1991 Aug;36(8):561–567. [PubMed] [Google Scholar]
  6. Ernest J. M. Topical antifungal agents. Obstet Gynecol Clin North Am. 1992 Sep;19(3):587–607. [PubMed] [Google Scholar]
  7. Fong I. W. The value of chronic suppressive therapy with itraconazole versus clotrimazole in women with recurrent vaginal candidiasis. Genitourin Med. 1992 Dec;68(6):374–377. doi: 10.1136/sti.68.6.374. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Horowitz B. J., Giaquinta D., Ito S. Evolving pathogens in vulvovaginal candidiasis: implications for patient care. J Clin Pharmacol. 1992 Mar;32(3):248–255. doi: 10.1002/j.1552-4604.1992.tb03833.x. [DOI] [PubMed] [Google Scholar]
  9. Horowitz B. J. Mycotic vulvovaginitis: a broad overview. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1188–1192. doi: 10.1016/s0002-9378(12)90725-5. [DOI] [PubMed] [Google Scholar]
  10. Neuhaus G., Pavic N., Pletscher M. Anaphylactic reaction after oral fluconazole. BMJ. 1991 Jun 1;302(6788):1341–1341. doi: 10.1136/bmj.302.6788.1341-b. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ng T. T., Denning D. W. Fluconazole resistance in Candida in patients with AIDS--a therapeutic approach. J Infect. 1993 Mar;26(2):117–125. doi: 10.1016/0163-4453(93)92707-4. [DOI] [PubMed] [Google Scholar]
  12. Nixon S. A. Vulvovaginitis: the role of patient compliance in treatment success. Am J Obstet Gynecol. 1991 Oct;165(4 Pt 2):1207–1209. doi: 10.1016/s0002-9378(12)90728-0. [DOI] [PubMed] [Google Scholar]
  13. Odds F. C. Resistance of yeasts to azole-derivative antifungals. J Antimicrob Chemother. 1993 Apr;31(4):463–471. doi: 10.1093/jac/31.4.463. [DOI] [PubMed] [Google Scholar]
  14. Osser S., Haglund A., Weström L. Treatment of candidal vaginitis. A prospective randomized investigator-blind multicenter study comparing topically applied econazole with oral fluconazole. Acta Obstet Gynecol Scand. 1991;70(1):73–78. doi: 10.3109/00016349109006182. [DOI] [PubMed] [Google Scholar]
  15. Patel H. S., Peters M. D., 2nd, Smith C. L. Is there a role for fluconazole in the treatment of vulvovaginal candidiasis? Ann Pharmacother. 1992 Mar;26(3):350–353. doi: 10.1177/106002809202600309. [DOI] [PubMed] [Google Scholar]
  16. Redondo-Lopez V., Lynch M., Schmitt C., Cook R., Sobel J. D. Torulopsis glabrata vaginitis: clinical aspects and susceptibility to antifungal agents. Obstet Gynecol. 1990 Oct;76(4):651–655. [PubMed] [Google Scholar]
  17. Scudamore J. A., Tooley P. J., Allcorn R. J. The treatment of acute and chronic vaginal candidosis. Br J Clin Pract. 1992 Winter;46(4):260–263. [PubMed] [Google Scholar]
  18. Slavin M. B., Benrubi G. I., Parker R., Griffin C. R., Magee M. J. Single dose oral fluconazole vs intravaginal terconazole in treatment of Candida vaginitis. Comparison and pilot study. J Fla Med Assoc. 1992 Oct;79(10):693–696. [PubMed] [Google Scholar]
  19. Sobel J. D. Candidal vulvovaginitis. Clin Obstet Gynecol. 1993 Mar;36(1):153–165. doi: 10.1097/00003081-199303000-00021. [DOI] [PubMed] [Google Scholar]
  20. Sobel J. D. Pathogenesis and treatment of recurrent vulvovaginal candidiasis. Clin Infect Dis. 1992 Mar;14 (Suppl 1):S148–S153. doi: 10.1093/clinids/14.supplement_1.s148. [DOI] [PubMed] [Google Scholar]
  21. Stein G. E., Christensen S., Mummaw N. Comparative study of fluconazole and clotrimazole in the treatment of vulvovaginal candidiasis. DICP. 1991 Jun;25(6):582–585. doi: 10.1177/106002809102500602. [DOI] [PubMed] [Google Scholar]
  22. Stein G. E., Mummaw N. Placebo-controlled trial of itraconazole for treatment of acute vaginal candidiasis. Antimicrob Agents Chemother. 1993 Jan;37(1):89–92. doi: 10.1128/aac.37.1.89. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Tett S., Carey D., Lee H. S. Drug interactions with fluconazole. Med J Aust. 1992 Mar 2;156(5):365–365. doi: 10.5694/j.1326-5377.1992.tb139816.x. [DOI] [PubMed] [Google Scholar]
  24. Timonen H. Shorter treatment for vaginal candidosis: comparison between single-dose oral fluconazole and three-day treatment with local miconazole. Mycoses. 1992 Nov-Dec;35(11-12):317–320. doi: 10.1111/j.1439-0507.1992.tb00887.x. [DOI] [PubMed] [Google Scholar]
  25. Tobin J. M., Loo P., Granger S. E. Treatment of vaginal candidosis: a comparative study of the efficacy and acceptability of itraconazole and clotrimazole. Genitourin Med. 1992 Feb;68(1):36–38. doi: 10.1136/sti.68.1.36. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infectious Diseases in Obstetrics and Gynecology are provided here courtesy of Wiley

RESOURCES